Nautilus Biotechnology, Inc. Payments of Stock Issuance Costs
Nautilus Biotechnology, Inc. (NAUT) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-02-23
- Nautilus Biotechnology, Inc. payments of stock issuance costs for the quarter ending 2022-12-31 was $0.00.
- Nautilus Biotechnology, Inc. payments of stock issuance costs for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Nautilus Biotechnology, Inc. payments of stock issuance costs for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Nautilus Biotechnology, Inc. payments of stock issuance costs for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Nautilus Biotechnology, Inc. payments of stock issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Nautilus Biotechnology, Inc. payments of stock issuance costs for fiscal 2021 was $8.13M.
- Nautilus Biotechnology, Inc. payments of stock issuance costs for fiscal 2020 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | $0.00 derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $47.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $47.00K derived: sum of 3 quarters · filed 2023-02-23 | $6.06M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $47.00K derived: sum of 2 quarters · filed 2023-02-23 | $6.06M derived: sum of 3 quarters · filed 2023-02-23 | $8.13M 10-K · filed 2023-02-23 |
| 2021-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $6.06M derived: sum of 2 quarters · filed 2022-11-01 | $8.13M 10-Q · filed 2022-11-01 | $8.13M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $6.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $8.08M 10-Q · filed 2022-08-02 | $8.08M derived: sum of 3 quarters · filed 2022-08-02 | $8.08M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $2.07M 10-Q · filed 2022-05-03 | $2.07M derived: sum of 2 quarters · filed 2022-05-03 | $2.07M derived: sum of 3 quarters · filed 2022-05-03 | |
| 2020-12-31 | $0.00 derived: 10-K 9 month − 10-Q 6 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-11-02 | $3.38M 10-K · filed 2021-03-30 | $0.00 10-K · filed 2022-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $3.38M 10-Q · filed 2020-11-13 | $0.00 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |